AGIO Share Price Performance
US$0
-39.07 (-100.00%)
Price US$0
Fair ValueUS$40.88
Share Pricen/a
Narrative Update • Jul 07
Agios Pharmaceuticals, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 14 Fair Values set on narratives written by author
AGIO Community Narratives
AN
Fair Value
·Fair Value US$40.88 4.7% overvalued intrinsic discount
FDA Approval And Global Partnerships Will Yield Mixed Prospects
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$57 24.9% undervalued intrinsic discount
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$31 38.0% overvalued intrinsic discount
Mounting Pricing Pressures And Delays Will Depress Future Outlook
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Mounting Pricing Pressures And Delays Will Depress Future Outlook
Agios relies heavily on one rare-disease drug, and the story hinges on whether tougher insurer pushback, tighter rules, and rising competition start to squeeze pricing and slow new approvals. The upside is real if new uses for its lead drug and a growing pipeline deliver, but the path could be bumpier than many expect.Read more
AN
US$31
38.0% overvalued intrinsic discount
Fair Value
Profit Margin
18.92%
Future PE
37.48x
Price in 2029
US$37.68
FDA Approval And Global Partnerships Will Yield Mixed Prospects
Agios is counting on its lead medicine to win new approvals and expand into more blood disorders, which could open up new patients in the U.S. and abroad through partnerships. But that same focus is a double-edged sword: safety questions, heavy spending, and slow international rollouts could limit how much growth actually shows up.Read more
AN
US$40.88
4.7% overvalued intrinsic discount
Fair Value
Profit Margin
19.04%
Future PE
38.11x
Price in 2029
US$49.7
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
Key Takeaways Accelerated global expansion and rapid market adoption are fueled by strong partnerships, clear patient targeting, and proactive payer and clinician engagement. Multiple near-term clinical advancements and pipeline synergies position Agios for transformative revenue growth and margin improvement, surpassing standard industry progress.Read more
AN
US$57
24.9% undervalued intrinsic discount
Fair Value
Revenue
124.92% p.a.
Profit Margin
14.17%
Future PE
64.24x
Price in 2028
US$68.9
Trending Discussion
Recently Updated Narratives
AN
AGIO: Sickle Cell Priority Review Momentum Will Limit Future Share Upside
Fair Value: US$31 38.0% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AGIO: Sickle Cell FDA Path And Thalassemia Launch Will Drive Next Phase Upside
Fair Value: US$40.88 4.7% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Precision Therapies Will Serve Aging Populations While Facing Regulatory Delays
Fair Value: US$57 24.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Agios Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
- -7.11
- -436.76%
- -639.84%
- 0%
About AGIO
- Founded
- 2007
- Employees
- 540
- CEO
- WebsiteView website
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company’s PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
